An observational study in Chest--Diseases, sponsored by Assiut University. Status unknown. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-09-25.
Sponsored by Assiut University · Observational
The objective of this study is to determine the pattern and outcome of respiratory diseases in adults patients admitted to the Department of Chest Diseases at Assiut University Hospital.
Respiratory diseases constitute an important global health burden. Pneumonia, tuberculosis, obstructive and restrictive lung diseases, pleural diseases, and malignancies are common respiratory conditions for hospital admission.Before the emergence of COVID-19, pneumonia, including community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP)/ventilation-associated pneumonia (VAP), was one of the most common infectious diseases, and could cause major health problems, associated with high morbidity and mortality in all age groups worldwide . The outbreak of COVID-19 has significantly changed the epidemiology of respiratory tract infection. More than 376 million people have been infected and 5 million have died in the whole world. This in addition to the long term post COVID pulmonary sequelae. Chronic obstructive pulmonary disease (COPD), lower respiratory tract infections, lung cancer and tuberculosis have been identified as top four respiratory diseases among ten leading causes of death worldwide. The forum of international respiratory societies (FIRS) estimated that 65 million people have moderate to severe COPD resulting in 3 million deaths per year, making it third leading cause of death worldwide .Currently, asthma affects an estimated 334 million people worldwide and is projected to increase to 400 million by the year 2025 .
In ;2015 10,4million people developed TB with 1.4 million global deaths were reported.
Neoplasms of the lungs are the leading cause of cancer incidence and mortality worldwide.
Assiut University is the lead sponsor of 5,050 studies on the registry; 2,174 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Prospective, descriptive and analytical study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Effect if treatment
Determine number of patients who experience improvement on discharge
Time frame: One year
Number of patient who Transferred to another hospital forcontintreatment
Time frame: One year
Number of patient died while on admission
Time frame: One year
Number of patient who Discharged against medical advice
Time frame: One year
No study locations are listed for this record.
This study is status unknown, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.